IDP-023 g-NK Cells

g-NK cells · Indapta Therapeutics, INC.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IDP-023 g-NK Cells, covering 2025-04-30 to 2025-04-30. Get the full timeline:

Most recent: Clinical Trial Update: IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis [Phase 1]